From: p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations
 | Primary Site | Diagnosis | P53 IHC | TP53 mutation type | Class | alteration | allele frquency | cbioportal | MDM2 amplification | Neoadjuvant treatment |
---|---|---|---|---|---|---|---|---|---|---|
group 1 | Large intestine | Adenocarcinoma | NT | WT | WT | ND | Â | negative | Not amplified | Done |
Large intestine | Adenocarcinoma | NT | WT | WT | ND | Â | negative | Not amplified | Done | |
Large intestine | Adenocarcinoma | NT | WT | WT | ND | Â | negative | Not amplified | Â | |
Large intestine | Adenocarcinoma | OE | WT | WT | ND | Â | negative | Not amplified | Â | |
Large intestine | Mucinous adenocarcinoma | OE | WT | WT | ND | Â | negative | Not amplified | Done | |
Large intestine | Adenocarcinoma | OE | WT | WT | ND | Â | negative | Not amplified | Â | |
Large intestine | Adenocarcinoma | OE | WT | WT | ND | Â | negative | Not amplified | Done | |
Anus | Adenocarcinoma | OE | WT | WT | ND | Â | negative | Not amplified | Done | |
Ovary | Papillary serous carcinoma | OE | WT | WT | ND | Â | negative | Not amplified | Done | |
Brain | Glioblastoma | OE | WT | WT | ND | Â | negative | Amplified | Â | |
group 2 | Large intestine | Adenocarcinoma | OE | truncation | LOF | R342* | 0.23 | Likely oncogenic | Not amplified | Â |
Large intestine | Adenocarcinoma | OE | splice site | LOF | X126_splice | 0.33 | Likely oncogenic | Not amplified | Done | |
Large intestine | Adenocarcinoma | OE | CNV loss | LOF | loss | 0 | unknown | Not amplified | Â | |
Large intestine | Adenocarcinoma | OE | splice site | LOF | X261_splice | 0.31 | Likely oncogenic | Not amplified | Â |